Last reviewed · How we verify

NCT04978831

The Effect of Use of Breathing Exercise Device and Reading Aloud on Vital Signs

Completed NA Last updated 31 March 2022
What this trial tests

NA trial testing PEP Device in Chronic Obstructive Pulmonary Disease in 131 participants. Completed in 31 January 2022.

Timeline
1 November 2020
Primary endpoint
3 January 2022
31 January 2022

Quick facts

Lead sponsorInonu University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment131
Start date1 November 2020
Primary completion3 January 2022
Estimated completion31 January 2022
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Inonu University

Who can join

18 and older, any sex, with Chronic Obstructive Pulmonary Disease or Breath Shortness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Purpose of the research; To determine the effects of wearable technology follow-up, breathing exercises with a breathing exercise device and reading aloud on vital signs, fatigue and respiratory function parameters in individuals with COPD. This research will be conducted using a randomized controlled trial model. "Personal Description Form", "COPD and Asthma Fatigue Scale", Visual Analog Scale and pulmonary function tests will be used in data collection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Chronic Obstructive Pulmonary Disease

Currently open trials in the same condition.

Other Inonu University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04978831.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing